Clinical trial
Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the…
NCT00043186 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00043186 |
|---|---|
| Title | Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density |
| Official title | A Randomized, Double-Blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women With Low Bone Mineral Density |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Low Bone Mineral Density |
| Intervention type | Drug |
| Interventions | Placebo, Denosumab, Alendronate |
| Enrollment | 412 |
| Start date | May 1, 2002 |
| Primary completion | Apr 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Aug 7, 2002 |
| Last update posted | Sep 18, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: